OncoMatch/Clinical Trials/NCT04803318

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Is NCT04803318 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Combination of three inhibitors Trametinib, Everolimus and Lenvatinib for solid tumor, adult.

Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical UniversityNCT04803318Data as of Jun 2026Location: China

Treatment: Combination of three inhibitors Trametinib, Everolimus and Lenvatinib — To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Targeted therapy

Combination of three inhibitors Trametinib, Everolimus and Lenvatinib

Cancer type

Tumor Agnostic

Hepatocellular Carcinoma

Demographics

Ages ≤ 85

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04803318 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 85 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Hepatocellular Carcinoma trials